- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | SyntheticMR AB (publ) appoints CFO Johanna Norén as Acting CEO | 2 | Cision News | ||
| Fr | Vedran Beglerbegovic appointed as new CEO of SyntheticMR AB (publ) | 2 | Cision News | ||
| SYNTHETICMR Aktie jetzt für 0€ handeln | |||||
| Do | SYNTHETICMR AB: SyntheticMR announces final outcome in the oversubscribed rights issue | 3 | Cision News | ||
| 14.01. | SYNTHETICMR AB: SyntheticMR's rights issue oversubscribed - preliminary outcome is announced | 1 | Cision News | ||
| 02.01. | SYNTHETICMR AB: SyntheticMR completes the acquisition of Combinostics Oy | 4 | Cision News | ||
| 20.12.24 | SYNTHETICMR AB: SyntheticMR publishes disclosure document regarding rights issue | 2 | Cision News | ||
| 17.12.24 | Announcement from extra general meeting in SyntheticMR AB (publ) | 1 | Cision News | ||
| 17.12.24 | XFRA CAPITAL ADJUSTMENT INFORMATION - 17.12.2024 | 128 | Xetra Newsboard | Das Instrument 14B NO0010776990 HUDDLY AS -,000625 EQUITY wird ex Kapitalmassnahme gehandelt am 17.12.2024 The instrument 14B NO0010776990 HUDDLY AS -,000625 EQUITY is traded ex capital adjustment on... ► Artikel lesen | |
| 13.12.24 | Spotlight Stock Market: Market Notice 263/24 - Information regarding the rights issue from SyntheticMR AB | 1 | Cision News | ||
| 06.12.24 | SYNTHETICMR AB: SyntheticMR receives FDA 510(k) clearance for SyMRI 15 | 4 | Cision News | ||
| 04.12.24 | SyntheticMR AB (publ) appoints Vedran Beglerbegovic as Acting CEO for SyntheticMR | 4 | Cision News | ||
| 28.11.24 | Notice of extra general meeting in SyntheticMR AB (publ) | 2 | Cision News | ||
| 28.11.24 | SYNTHETICMR AB: SyntheticMR resolves on a rights issue of approximately SEK 65 million | 4 | Cision News | ||
| 28.11.24 | SYNTHETICMR AB: SyntheticMR signs agreement to acquire Finnish Combinostics Oy | 1 | Cision News | ||
| 22.11.24 | SYNTHETICMR AB: Nomination Committee appointed for the 2025 Annual General Meeting in SyntheticMR | 1 | Cision News | ||
| 18.11.24 | SYNTHETICMR AB: Interim report July - September 2024 | 3 | Cision News | ||
| 06.11.24 | SyntheticMR AB (publ) brings forward the publication date of the interim report for the period 1 January - 30 September 2024 to Monday, 18 November 2024. | 1 | Cision News | ||
| 29.10.24 | SYNTHETICMR AB: SyntheticMR Receives Regulatory Approval for SyMRI 15 in Australia | 4 | Cision News | ||
| 02.10.24 | SyntheticMR AB: SyntheticMR Receives Regulatory Approval for SyMRI 15 in Switzerland | 351 | PR Newswire | LINKÖPING, Sweden, Oct. 2, 2024 /PRNewswire/ -- SyntheticMR AB, global leader in advanced quantitative imaging software, is pleased to announce that its SyMRI 15 solution has received regulatory... ► Artikel lesen | |
| 25.09.24 | SYNTHETICMR AB: SyntheticMR Announces Regulatory Clearance for SyMRI 15 in the UK | 1 | Cision News |
Seite:
1 2 Weiter >>
26 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BRIGHTSPRING HEALTH SERVICES | 20,890 | 0,00 % | BrightSpring Health Services, Inc. Enters into Definitive Agreement to Divest Community Living Business to Sevita; Reports Preliminary 2024 Financial Results and Provides 2025 Guidance Excluding Community Living | Streamlined organization and Provider Services segment to optimize resource allocationProvider Services focus on Home Health/Hospice, Personal Care, Rehabilitation Services, and Care Management strategic... ► Artikel lesen | |
| ATRICURE | 39,630 | 0,00 % | AtriCure (NASDAQ:ATRC) Hits New 52-Week High - Should You Buy? | ||
| PROCEPT BIOROBOTICS | 69,72 | 0,00 % | PROCEPT BioRobotics (NASDAQ:PRCT) Trading Down 2.8% - Should You Sell? | ||
| SIEMENS HEALTHINEERS | 54,26 | +0,89 % | Siemens Healthineers-Aktie: Kurs klettert leicht (53,42 €) | Am deutschen Aktienmarkt liegt das Wertpapier von Siemens Healthineers aktuell im Plus. Die Aktie kostete zuletzt 53,42 Euro. Die Aktie von Siemens Healthineers verzeichnet gegenwärtig einen Wertanstieg... ► Artikel lesen | |
| GERRESHEIMER | 66,35 | -1,04 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 48,940 | +0,29 % | JPMORGAN stuft CARL ZEISS MEDITEC AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Carl Zeiss Meditec mit einem Kursziel von 40 Euro auf "Underweight" belassen. Das erste Geschäftsquartal dürfte mau ausfallen... ► Artikel lesen | |
| GENEDX | 74,33 | 0,00 % | GeneDx Announces Preliminary 2024 Financial Results | STAMFORD, Conn.--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, today reported preliminary financial results for... ► Artikel lesen | |
| FRESENIUS | 36,210 | 0,00 % | DAX-Check LIVE: Fresenius, Hypoport, Kontron, Lanxess, Nemetschek, Nordex, Porsche AG, RWE, SAP & Co | Der DAX hat gestern die nächste Tausendermarke übersprungen. Erstmalig überwand er 21.000 Punkte. Am Ende des Tages ging er knapp darunter aus dem Handel. Das Tagesplus betrug 0,42 Prozent. Worauf es... ► Artikel lesen | |
| RXSIGHT | 30,920 | 0,00 % | RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance | ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) - RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following... ► Artikel lesen | |
| PROGYNY | 21,470 | 0,00 % | Progyny beruft Gesundheitsexpertin Debra Morris in den Vorstand | ||
| ALIGNMENT HEALTHCARE | 14,555 | 0,00 % | Alignment Healthcare is latest to sue Medicare over Star Ratings | ||
| NANO-X IMAGING | 8,365 | 0,00 % | Nano-X Imaging LTD.: Nanox.ARC Imaging System Receives FDA Clearance for General Use, Including Pulmonary Indication | Nanox.ARC receives additional FDA clearance to produce tomographic images for general use, including pulmonary, intra-abdominal and paranasal indications, in addition to its previously cleared indication... ► Artikel lesen | |
| TREACE MEDICAL CONCEPTS | 9,270 | 0,00 % | Treace Medical Concepts, Inc.: Treace Appoints Guy Guglielmino as Chief Commercial Officer | PONTE VEDRA, Fla., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical... ► Artikel lesen | |
| HELIUS MEDICAL | 1,010 | 0,00 % | Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target | --128 enrolled participants, as of December 31, 2024, exceeds initial target of 90 participants-- --150 maximum participant enrollment projected by end of January-- --The stroke registrational program... ► Artikel lesen | |
| CASTLE BIOSCIENCES | 26,680 | 0,00 % | Castle Biosciences CEO Derek Maetzold verkauft Aktien im Wert von 71.902 US-Dollar |
Das Unternehmen SYNTHETICMR AB kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -9,37 % bei einem Aktienkurs von 0,416 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SYNTHETICMR AB finden Sie auf Wallstreet Online.
